You are here: Industry Insights > Market News > Unichem Labs gets USFDA approval for Guanfacine Tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Unichem Labs gets USFDA approval for Guanfacine Tablets

expresspharmaMarch 05, 2021

Tag: Unichem , FDA , Guanfacine Tablets

Favorites

Unichem Laboratories has received ANDA approval for its Guanfacine Tablets, USP 1 mg and 2 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENEX (Guanfacine) Tablets 1 mg and 2 mg of Promius Pharma.

Guanfacine Tablets are indicated in the management of hypertension. The product will be commercialised from Unichem’s Ghaziabad Plant.

Previous:Laurus Labs promoters sell 52 lakh equity shares at aggregate Rs 191.67 crores

Next:Vivimed Labs’ FDF facility in Jeedimetla gets renewed GMP approval from Ukraine

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Unichem Labs gets USFDA approval for Guanfacine Tablets | Pharmasources.com

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

Unichem Labs gets USFDA approval for Guanfacine Tablets

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

You may like